Donald Trump's decision to appoint Robert F. Kennedy Jr. as Secretary of Health and Human Services has sent shockwaves through the pharmaceutical industry. Known for his skepticism towards big pharma, RFK Jr.'s appointment signals a potential overhaul in how the industry might be regulated. Historically, the HHS has been perceived as lenient towards pharmaceutical giants. Kennedy's tenure could usher in a new era of scrutiny, with powers to replace current administrators, potentially those seen as too accommodating to the industry. This move could challenge the status quo, aiming to curb what many see as pharmaceutical overreach and unethical practices.